Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-2104-2025

VersaCross RF Wire (VXW). Indicated for creation of an atrial septal defect in the heart. Product ID VXW0002 Device approved and commercialized in Japan only. Recall

VersaCross RF Wire (VXW). Indicated for creation of an atrial septal defect in the heart. Product ID VXW0002 Device approved and commercialized in Japan only.

FDA recall Class II

Ongoing

FDA lists this Class II recall for VersaCross RF Wire (VXW). Indicated for creation of an atrial septal defect in the heart. Product ID VXW0002 Device approved and commercialized in Japan only.. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-2104-2025
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Jun 10, 2025
FDA report date
Jul 16, 2025
Quantity in commerce
14,724
Distribution
See key details
FDA cause
Packaging change control

What is being recalled?

VersaCross RF Wire (VXW). Indicated for creation of an atrial septal defect in the heart. Product ID VXW0002 Device approved and commercialized in Japan only.

Affected model & UDI checker

Search the exact identifiers published for Z-2104-2025.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
Not specifiedVersaCross RF Wire (VXW). Indicated for creation of an atrial septal defect in the heart. Product ID VXW0002 Device approved and commercialized in Japan only.Check source notice00685447006121
FDA code information

UDI-DI 00685447006121 Lot 35935598

View the original FDA recall notice

Why was this product recalled?

Potential for hole in the Tyvek layer of the sterile barrier pouch, which may compromise device sterility. Issue could potentially lead to systemic infection and sepsis in worst case scenario. Potential punctures may go undetected in clinical settings due to small size and variable location.

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did BOSTON SCIENTIFIC CORPORATION take?

On June 10, 2025, the firm began notifying consignees of the field action via Urgent Medical Device Removal letters. Customers are instructed to not use affected product. They should remove affected units from their inventory and segregate the units in a secure place until they can be returned to Boston Scientific.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology